These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36915864)

  • 21. Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring.
    Barg AA; Budnik I; Avishai E; Brutman-Barazani T; Bashari D; Misgav M; Lubetsky A; Kuperman AA; Livnat T; Kenet G
    Haemophilia; 2021 May; 27(3):383-391. PubMed ID: 33892524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.
    Kruse-Jarres R; Peyvandi F; Oldenburg J; Chang T; Chebon S; Doral MY; Croteau SE; Lambert T; Kempton CL; Pipe SW; Ko RH; Trzaskoma B; Dhalluin C; Bienz NS; Niggli M; Lehle M; Paz-Priel I; Young G; Jiménez-Yuste V
    Blood Adv; 2022 Dec; 6(24):6140-6150. PubMed ID: 35939785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A.
    Retout S; Schmitt C; Petry C; Mercier F; Frey N
    Clin Pharmacokinet; 2020 Dec; 59(12):1611-1625. PubMed ID: 32504271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
    Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 26. Real-world cost estimates of initiating emicizumab in US patients with haemophilia A.
    Samelson-Jones BJ; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Raffini L
    Haemophilia; 2021 Jul; 27(4):591-598. PubMed ID: 34050689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY).
    Jiménez-Yuste V; Peyvandi F; Klamroth R; Castaman G; Shanmukhaiah C; Rangarajan S; García Chavez J; Martinez R; Kenet G; Alzahrani H; Robson S; Schmitt C; Kiialainen A; Meier O; Ozelo M
    Res Pract Thromb Haemost; 2022 Nov; 6(8):e12837. PubMed ID: 36397934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
    Nakajima Y; Mizumachi K; Shimonishi N; Furukawa S; Yada K; Ogiwara K; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2022 Apr; 115(4):489-498. PubMed ID: 35043383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
    Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
    J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.
    Shima M; Amano K; Ogawa Y; Yoneyama K; Ozaki R; Kobayashi R; Sakaida E; Saito M; Okamura T; Ito T; Hattori N; Higasa S; Suzuki N; Seki Y; Nogami K
    J Thromb Haemost; 2023 Mar; 21(3):534-545. PubMed ID: 36696195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.
    Klamroth R; Wojciechowski P; Aballéa S; Diamand F; Hakimi Z; Nazir J; Abad-Franch L; Lethagen S; Santagostino E; Tarantino MD
    J Blood Med; 2021; 12():115-122. PubMed ID: 33664606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A.
    Sun SX; Frick A; Balasa V; Roberts JC
    Expert Rev Hematol; 2022 Oct; 15(10):943-950. PubMed ID: 36000620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
    Kiialainen A; Niggli M; Kempton CL; Castaman G; Chang T; Paz-Priel I; Adamkewicz JI; Levy GG
    Haemophilia; 2022 Nov; 28(6):1033-1043. PubMed ID: 35905294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
    Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
    Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.
    Kruse-Jarres R; Oldenburg J; Santagostino E; Shima M; Kempton CL; Kessler CM; Lehle M; Chebon S; Selak Bienz N; Asikanius E; Mahlangu J
    Haemophilia; 2019 Mar; 25(2):213-220. PubMed ID: 30724422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe.
    Mancuso ME; Castaman G; Pochopien M; Aballéa S; Drzewiecka A; Hakimi Z; Nazir J; Fatoye F
    J Med Econ; 2022; 25(1):1068-1075. PubMed ID: 35993970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low immunogenicity of emicizumab in persons with haemophilia A.
    Schmitt C; Emrich T; Chebon S; Fernandez E; Petry C; Yoneyama K; Kiialainen A; Howard M; Niggli M; Paz-Priel I; Chang T
    Haemophilia; 2021 Nov; 27(6):984-992. PubMed ID: 34480814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emicizumab for the prevention of bleeds in hemophilia A.
    Mahlangu J
    Expert Opin Biol Ther; 2019 Aug; 19(8):753-761. PubMed ID: 31150297
    [No Abstract]   [Full Text] [Related]  

  • 40. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
    Skinner MW; Négrier C; Paz-Priel I; Chebon S; Jiménez-Yuste V; Callaghan MU; Lehle M; Niggli M; Mahlangu J; Shapiro A; Shima M; Campinha-Bacote A; Levy GG; Oldenburg J; von Mackensen S; Pipe SW
    Haemophilia; 2021 Sep; 27(5):854-865. PubMed ID: 34171159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.